Dr. Gross received a masters (M.S.) in Biology from the California State University and his doctorate (Ph.D.) in Cell Biology from the University of California, Los Angeles. He did his postdoctoral training at Tulane University School of Medicine. He has also done postgraduate programs at the Wharton School, Harvard/Tufts Law Schools and MIT. Dr. Gross is also faculty in the Jefferson College of Biomedical Sciences and the Sydney Kimmel Medical College of Thomas Jefferson University, Professor of Experimental Therapeutics and Medicinal Chemistry in the Blumberg Institute and Adjunct Professor of Basic Sciences at The Commonwealth Medical College. He has published more than 120 scientific publications. He currently is also the CEO of the Pennsylvania Drug Discovery Institute.
Dr. Beyer is President & CEO of Promentis Pharmaceuticals, Inc. He has nearly 20 years of experience in the research, discovery and business development of medications aimed to treat CNS and neurological disorders. Previously, Dr. Beyer served as the Head of Neurochemistry at Wyeth Pharmaceuticals in Princeton, NJ. During his career at Wyeth, Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, 3 patents, and co-edited "Next Generation Antidepressants." Dr. Beyer is also an adjunct faculty member at Thomas Jefferson University in Philadelphia where he teaches "Bioventure Management", a class focused on the business of doing science.